Insights into the pathogenesis of rheumatic and immune diseases from single-cell omics

High-resolution, high-throughput single-cell omics has transformed our understanding of autoimmune disease pathogenesis. We synthesise recent single-cell omics advances across six autoimmune diseases—systemic sclerosis, systemic lupus erythematosus, Sjögren’s syndrome, ankylosing spondylitis, IgG4-related disease and rheumatoid arthritis. We further summarise translational progress in targeted therapies. We delineate core pathological networks shared across these conditions, highlight convergent mechanisms, and provide a mechanistic rationale for the clinical activity of agents such as tofacitinib and abatacept across multiple autoimmune settings. These insights support the feasibility of mechanism-informed, cross-disease targeting—deploying shared pathway interventions across distinct clinical entities. Finally, we discuss current technical and interpretative challenges and outline future directions for mechanistic discovery, target prioritisation and precision medicine.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-03-12
DOI
https://doi.org/10.3389/fimmu.2026.1768719
Primary Topic
Systemic Sclerosis and Related Diseases
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Insights into the pathogenesis of rheumatic and immune diseases from single-cell omics

S. Zhang, Dongbao Zhao, Yingjie Jiang, Wei Wan
Frontiers in Immunology
Systemic Sclerosis and Related Diseases
article

Insights into the pathogenesis of rheumatic and immune diseases from single-cell omics

S. Zhang, Dongbao Zhao, Yingjie Jiang, Wei Wan
article en

Abstract

High-resolution, high-throughput single-cell omics has transformed our understanding of autoimmune disease pathogenesis. We synthesise recent single-cell omics advances across six autoimmune diseases—systemic sclerosis, systemic lupus erythematosus, Sjögren’s syndrome, ankylosing spondylitis, IgG4-related disease and rheumatoid arthritis. We further summarise translational progress in targeted therapies. We delineate core pathological networks shared across these conditions, highlight convergent mechanisms, and provide a mechanistic rationale for the clinical activity of agents such as tofacitinib and abatacept across multiple autoimmune settings. These insights support the feasibility of mechanism-informed, cross-disease targeting—deploying shared pathway interventions across distinct clinical entities. Finally, we discuss current technical and interpretative challenges and outline future directions for mechanistic discovery, target prioritisation and precision medicine.

Frontiers in ImmunologyVol. 17
Naval Medical Research Command (US)
National Natural Science Foundation of China
Openalex Percentile: Top 25%
Systemic Sclerosis and Related Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.